Literature DB >> 16905106

The crystal structure of the costimulatory OX40-OX40L complex.

Deanne M Compaan1, Sarah G Hymowitz.   

Abstract

OX40 is a T cell costimulator activated by OX40L. Blockade of the OX40L-OX40 interaction has ameliorative effects in animal models of T cell pathologies. In order to better understand the interaction between OX40 and OX40L, we have determined the crystal structure of murine OX40L and of the human OX40-OX40L complex at 1.45 and 2.4 A, respectively. These structures show that OX40L is an unusually small member of the tumor necrosis factor superfamily (TNFSF). The arrangement of the OX40L protomers forming the functional trimer is atypical and differs from that of other members by a 15 degrees rotation of each protomer with respect to the trimer axis, resulting in an open assembly. Site-directed changes of the interfacial residues of OX40L suggest this interface lacks a single "hot spot" and that instead, binding energy is dispersed over at least two distinct areas. These structures demonstrate the structural plasticity of TNFSF members and their interactions with receptors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16905106     DOI: 10.1016/j.str.2006.06.015

Source DB:  PubMed          Journal:  Structure        ISSN: 0969-2126            Impact factor:   5.006


  61 in total

1.  OX40 ligand fusion protein delivered simultaneously with the BCG vaccine provides superior protection against murine Mycobacterium tuberculosis infection.

Authors:  Robert J Snelgrove; Megan M Cornere; Lorna Edwards; Belinda Dagg; James Keeble; Angela Rodgers; Daphne E Lyonga; Graham R Stewart; Douglas B Young; Barry Walker; Tracy Hussell
Journal:  J Infect Dis       Date:  2012-02-07       Impact factor: 5.226

Review 2.  Signaling through OX40 enhances antitumor immunity.

Authors:  Shawn M Jensen; Levi D Maston; Michael J Gough; Carl E Ruby; William L Redmond; Marka Crittenden; Yuhuan Li; Sachin Puri; Christian H Poehlein; Nick Morris; Magdalena Kovacsovics-Bankowski; Tarsem Moudgil; Chris Twitty; Edwin B Walker; Hong-Ming Hu; Walter J Urba; Andrew D Weinberg; Brendan Curti; Bernard A Fox
Journal:  Semin Oncol       Date:  2010-10       Impact factor: 4.929

3.  Comparative genomic analysis of eutherian tumor necrosis factor ligand genes.

Authors:  Marko Premzl
Journal:  Immunogenetics       Date:  2015-12-09       Impact factor: 2.846

4.  CD137-CRDI is not necessary in the role of contacting its natural ligand.

Authors:  Ling Yi; Zhuohong Yan; Hongyan Jia; Xiaojue Wang; Yanlin Zhao; Hongtao Zhang
Journal:  Immunol Cell Biol       Date:  2016-08-16       Impact factor: 5.126

Review 5.  Sequence, structure, function, immunity: structural genomics of costimulation.

Authors:  Kausik Chattopadhyay; Eszter Lazar-Molnar; Qingrong Yan; Rotem Rubinstein; Chenyang Zhan; Vladimir Vigdorovich; Udupi A Ramagopal; Jeffrey Bonanno; Stanley G Nathenson; Steven C Almo
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

Review 6.  Targeting lymphocyte activation through the lymphotoxin and LIGHT pathways.

Authors:  Carl F Ware
Journal:  Immunol Rev       Date:  2008-06       Impact factor: 12.988

7.  Crystal structure of the human 4-1BB/4-1BBL complex.

Authors:  Ryan N Gilbreth; Vaheh Y Oganesyan; Hamza Amdouni; Shabazz Novarra; Luba Grinberg; Arnita Barnes; Manuel Baca
Journal:  J Biol Chem       Date:  2018-05-02       Impact factor: 5.157

8.  Crystal structures of the human 4-1BB receptor bound to its ligand 4-1BBL reveal covalent receptor dimerization as a potential signaling amplifier.

Authors:  Aruna Bitra; Tzanko Doukov; Michael Croft; Dirk M Zajonc
Journal:  J Biol Chem       Date:  2018-05-02       Impact factor: 5.157

9.  Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein.

Authors:  Michael D Oberst; Catherine Augé; Chad Morris; Stacy Kentner; Kathy Mulgrew; Kelly McGlinchey; James Hair; Shino Hanabuchi; Qun Du; Melissa Damschroder; Hui Feng; Steven Eck; Nicholas Buss; Lolke de Haan; Andrew J Pierce; Haesun Park; Andrew Sylwester; Michael K Axthelm; Louis Picker; Nicholas P Morris; Andrew Weinberg; Scott A Hammond
Journal:  Mol Cancer Ther       Date:  2018-03-15       Impact factor: 6.261

Review 10.  The promise and challenges of immune agonist antibody development in cancer.

Authors:  Patrick A Mayes; Kenneth W Hance; Axel Hoos
Journal:  Nat Rev Drug Discov       Date:  2018-06-15       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.